Structure Therapeutics Q2 FY26 net loss widens to $106.16 million; R&D expenses rise to $100.06 million

• Structure Therapeutics posted a Q2 net loss of $106.16 million, widening from $61.66 million a year earlier.
• R&D expense climbed to $100.06 million from $54.71 million; G&A rose to $18.57 million from $15.74 million.
• Cash, cash equivalents and short-term investments fell to $1.34 billion as of June 30, 2026, from $1.45 billion at year-end 2025.
• First patients were dosed in the Phase 3 ACCOMPLISH-1 and -2 program for aleniglipron in chronic weight management.
• Initial Phase 1 ACCG-2671 SAD data and a MAD trial start are targeted for Q3 2026; ACCESS OLE topline 72-week data are also due Q3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061605PRIMZONEFULLFEED9805469) on August 06, 2026, and is solely responsible for the information contained therein.